Sanofi, Regeneron PCSK9 trial uses new recruitment tool

Share this article:

Sanofi, Regeneron and the American College of Cardiology announced Thursday that they were taking a team approach to an investigational monoclonal antibody that will target PCSK9, which is associated with LDL levels. The trio will investigate alirocumab, which Sanofi and Regeneron are developing.

The agreement means the ACC's contribution will include identifying Phase III Odyssey Outcomes clinical trial candidates using its Pinnacle registry—the registry's first use for clinical trial recruitment—and assisting with physician- and patient- education programs regarding “the value of clinical trial research.”

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions